Detalhe da pesquisa
1.
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
Adv Ther
; 39(7): 3146-3158, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35543964